

**Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis.**

Thibaud Damy, Jean-François Deux, Stéphane Moutereau, Soulef Guendouz, Dania Mohty, Stéphane Rappeneau, Aziz Guellich, Luc Hittinger, Sylvain Loric, Jean-Pascal Lefaucheur, et al.

► **To cite this version:**

Thibaud Damy, Jean-François Deux, Stéphane Moutereau, Soulef Guendouz, Dania Mohty, et al.. Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis.: Cardiac biomarkers in FAP. Amyloid: The Journal of Protein Folding Disorders, Taylor & Francis, 2013, 20 (4), pp.212-20. <10.3109/13506129.2013.825240>. <inserm-00856266>

**HAL Id: inserm-00856266**

**<http://www.hal.inserm.fr/inserm-00856266>**

Submitted on 12 Aug 2014

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Table 1: Baseline clinical, biological, and treatment characteristics of subjects according to phenotype.**

Phenotypes	Asymptomatic	Neurological	Cardiac with or without neurological	p
<b>N</b>	4	6	26	
<b>Genetic mutation</b>				
<i>ATTR</i> Val30Met, <i>n</i> (%)	3 (80)	5 (83)	11 (42)	na
<b>Clinical variables</b>				
Age, years	48 (33; 56)	40 (35; 49)	65 (56; 74)	0.006
Weight, kg	73 (63; 80)	59 (53; 72)	71 (57; 75)	0.32
BMI, kg/m <sup>2</sup>	24 (22; 25)	24 (22; 28)	23 (20; 26)	0.58
Men, <i>n</i> (%)	3(75)	0	20(77)	0.002
SBP, mmHg	140 (136; 162)	110 (105; 132)	120 (110; 130)	0.045
DBP, mmHg	80 (75; 97)	70 (63; 86)	80 (70; 80)	0.59
HR, bpm	74 (69; 91)	80 (69; 86)	80 (69; 86)	0.39
NYHA class (3; 4), %	0	0	2 (8)	0.67
History of decompensated HF	0	0	5 (19)	0.27
Carpal-tunnel syndrome or history of decompression, %	0	0	14 (54)	0.018
Peripheral neuropathy, <i>n</i> (%)	0	6(100)	21(81)	0.001
<b>Dysautonomia</b>				
Gastric and gut, <i>n</i> (%)	0	4 (67)	15 (58)	0.08
Orthostatic hypotension, <i>n</i> (%)	0	0	5 (19)	0.33
Erectile dysfunction, <i>n</i> (%)	0	0	13 (50)	0.02
Urinary dysfunction, <i>n</i> (%)	0	1 (17)	2 (8)	0.63
<b>Electrocardiogram</b>				
PR interval, (ms)	144 (123; 175)	179 (162; 198)	190 (146; 220)	0.19
QRS interval, (ms)	85 (80; 101)	96 (76; 109)	98 (80; 120)	0.42
<b>Treatment</b>				
Liver transplant, <i>n</i> (%)	0	3 (50)	5 (19)	0.33
Cardiac-pacemaker implant, <i>n</i> (%)	0	0	14 (56)	0.007
<b>Biological variables</b>				
NT- proBNP, pg/ml	33 (19; 50)	54 (37; 154)	747 (253; 2840)	0.001
cTnT, ng/ml	0.01	0.01	0.24 (0.01; 0.05)	0.02
Creatinine, μmol/l	82 (67; 92)	71 (61; 100)	83 (69; 101)	0.69
Hemoglobin, g/dl	14.4 (13.2; 15.7)	12.7 (12.1; 13.6)	12.7 (12.0; 14.1)	0.21

BMI: body-mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate.

**Table 2: Baseline echocardiographic characteristics in subjects according to phenotype.**

<b>Phenotype:</b>	<b>Asymptomatic</b>	<b>Neurological</b>	<b>Cardiac with or without neurological</b>	
<b>Echocardiographic variables</b>				
<b>N</b>	4	6	26	
<b>LV variables</b>				
LVEDD, mm	50 (48; 53)	47 (41; 49)	43 (40; 49)	0.14
LVESD, mm	30 (28; 31)	29 (23; 30)	29 (25; 35)	0.61
IVST, mm	9 (8; 9)	9 (8; 10)	16 (12; 19)	0.0001
LVPWTD, mm	8 (7; 9)	9 (8; 9)	14 (10;16)	0.0001
LVEF, mm	61 (59; 73)	65 (60; 67)	60 (46; 63)	0.20
LV 2D strain, %	-19 (-17; -20)	-19 (-18; -22)	-12 (-10; -15)	0.004
LVM, g	143 (126; 178)	141 (125; 152)	258 (213; 383)	0.002
LVMind, g/m <sup>2</sup>	79 (68; 90)	93 (70; 95)	143 (119; 217)	0.001
E, cm	163 (129; 180)	75 (73; 84)	74 (59; 104)	0.64
A, cm	61 (46; 75)	57 (45; 77)	58 (39; 74)	0.63
E/A	1.5 (1.0; 1.7)	1.3 (1.1; 1.7)	1.3 (0.8; 2.5)	0.98
E/Ea	6 (6; 7)	7 (7; 9)	12 (6; 20)	0.14
<b>Other variables</b>				
Ao, mm	30 (26; 30)	28 (24; 31)	32 (29;36)	0.025
LA, mm	37 (30; 38)	34 (28; 38)	40 (35; 47)	0.042
SPAP, mmHg*	20	20	41(27; 59)	0.24
TAPSE, mm	26 (25; 27)	19 (18; 23)	17 (13; 22)	0.023
Pericardial effusion, %	0	1 (17)	9 (35)	0.29

LVEDD: left ventricular end-diastolic diameter; IVST: inter-ventricular septal thickness, and LVPWT: left ventricular posterior wall thickness; LV 2D strain: LV systolic function; LVM; LVM: left ventricular mass as marker of amyloid deposits; LVMind: LVM indexed by the body surface area; E: peak of early transmitral wave in pulsed Doppler; A: peak of atrial transmitral wave in pulsed wave Doppler; Ea: mean of early septal and lateral diastolic peak measured in tissue Doppler imaging; Ao: aortic diameter; LA: left atria diameter; SPAP: systolic pulmonary artery pressure; TAPSE: tricuspid annular plane systolic excursion. \*Only measureable in patients with tricuspid regurgitation ( $n=16$ ).